Finder's Pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Acceleron Pharma is a biotechnology business based in the US. Acceleron Pharma stocks (XLRN.US) are listed on the NASDAQ and all prices are listed in US Dollars. Acceleron Pharma employs 312 staff and has a trailing 12-month revenue of around $112.8 million.
|52-week range||$113.49 - $189.99|
|50-day moving average||$169.49|
|200-day moving average||$137.95|
|Wall St. target price||$178.88|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-4.20|
Note: The dollar amounts in the table below are in Canadian dollars.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
|1 week (2022-05-13)||N/A|
|1 month (2022-04-20)||N/A|
|3 months (2022-02-20)||N/A|
|6 months (2021-11-20)||N/A|
|1 year (2021-05-24)||-100.00%|
|2 years (2020-05-22)||-100.00%|
|3 years (2019-05-23)||-100.00%|
|5 years (2017-05-23)||-100.00%|
|Revenue TTM||$112.8 million|
|Gross profit TTM||$-81,394,000|
|Return on assets TTM||-18.4%|
|Return on equity TTM||-31.59%|
|Market capitalisation||$10.9 billion|
TTM: trailing 12 months
We're not expecting Acceleron Pharma to pay a dividend over the next 12 months.
Over the last 12 months, Acceleron Pharma's shares have ranged in value from as little as $113.49 up to $189.99. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Acceleron Pharma's is 0.1314. This would suggest that Acceleron Pharma's shares are less volatile than average (for this exchange).
Acceleron Pharma Inc. , a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. It offers REBLOZYL (luspatercept-aamt), a first-in-class erythroid maturation agent, for the treatment of anemia in adult patients with beta-thalassemia and transfusion-dependent anemia. The company is also developing Sotatercept, an activin receptor type IIA fusion protein, for the treatment of patients with pulmonary arterial hypertension; ACE-1334, a pulmonary therapeutic candidate that is in Phase I clinical trials; and luspatercept-aamt for non-transfusion-dependent beta-thalassemia patients and lower-risk myelodysplastic syndrome patients. It has a license agreements with the Salk Institute for Biological Studies for the cloning of type II activin receptors; and license agreement with Fulcrum Therapeutics, Inc. to identify small molecules designed to modulate specific pathways associated with a targeted indication within the pulmonary disease space. The company was formerly known as Phoenix Pharma, Inc.
iGaming is now legal in Ontario. Find out which companies to keep an eye on with our list of 10 top online gaming stocks.Read more…
Enjoy perks like free trades and cash rewards when you open a stock trading account with these online brokers.Read more…
Here’s what you need to know about investing in the propane industry, including 3 popular propane stocks to watch.Read more…
Learn more about apps like Wealthsimple to find the best trading platform for your unique set of needs.
iGaming is now legal in Ontario. Find out which companies to keep an eye on with our list of 10 top online gaming stocks.
Steps to owning and managing ENT stock, with 24-hour and historical pricing before you buy.
Steps to owning and managing KAMBI stock, with 24-hour and historical pricing before you buy.
Enjoy perks like free trades and cash rewards when you open a stock trading account with these online brokers.
Steps to owning and managing RSI stock, with 24-hour and historical pricing before you buy.
Steps to owning and managing PBTHF stock, with 24-hour and historical pricing before you buy.
Everything we know about the Hanover Bancorp, Inc. IPO, plus information on how to buy in.
Everything we know about the PrimeBlock IPO, plus information on how to buy in.
Everything we know about the Actelis Networks IPO, plus information on how to buy in.
You must be logged in to post a comment.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.